CVRx reports Q2 EPS (57c), consensus (52c)

Reports Q2 revenue $13.59M, consensus $13.22M. “We delivered solid second quarter results and continued to build momentum across our business,” said Kevin Hykes, president and CEO of CVRx (CVRX). “Our sales force transformation is gaining traction, and we’re building sustainable Barostim programs with high potential centers. We continue to make progress on multiple fronts by advancing our clinical evidence strategy and strengthening our reimbursement position, including CMS’ proposal to keep Barostim in APC 1580 with appropriate payment for the implant procedure. The fundamentals of our business remain strong, and our maturing commercial organization positions us well for continued growth.”